Embecta Corp. (EMBC)
NASDAQ: EMBC · IEX Real-Time Price · USD
13.17
-0.18 (-1.35%)
At close: Jul 19, 2024, 4:00 PM
13.22
+0.05 (0.38%)
Pre-market: Jul 20, 2024, 9:28 AM EDT
Embecta Revenue
Embecta had revenue of $1.13B in the twelve months ending March 31, 2024, with 1.25% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $287.20M with 3.64% year-over-year growth. In the fiscal year ending September 30, 2023, Embecta had annual revenue of $1.12B.
Revenue (ttm)
$1.13B
Revenue Growth
+1.25%
P/S Ratio
0.67
Revenue / Employee
$514,773
Employees
2,200
Market Cap
759.52M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2023 | 1.12B | -8.70M | -0.77% |
| Sep 30, 2022 | 1.13B | -35.80M | -3.07% |
| Sep 30, 2021 | 1.17B | 79.80M | 7.35% |
| Sep 30, 2020 | 1.09B | -23.50M | -2.12% |
| Sep 30, 2019 | 1.11B | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Phibro Animal Health | 999.56M |
| Evolus | 219.70M |
| Travere Therapeutics | 183.23M |
| OrthoPediatrics | 161.83M |
| Simulations Plus | 66.98M |
| 4D Molecular Therapeutics | 20.45M |
| Abivax | 5.13M |
| Dianthus Therapeutics | 2.26M |
EMBC News
- 3 days ago - embecta to Report Fiscal Third Quarter 2024 Financial Results - GlobeNewsWire
- 4 weeks ago - embecta-sponsored Abstracts Presented at American Diabetes Association's 84th Scientific Sessions Highlight Unmet Need for Patch Pumps with 300u Insulin Reservoir - GlobeNewsWire
- 4 weeks ago - Zimmer Biomet Announces Appointment of Devdatt Kurdikar to Board of Directors - PRNewsWire
- 2 months ago - Embecta Corp. Reports Second Quarter Fiscal 2024 Financial Results - GlobeNewsWire
- 2 months ago - embecta Announces Quarterly Cash Dividend - GlobeNewsWire
- 2 months ago - embecta to Participate in Investor Events - GlobeNewsWire
- 3 months ago - embecta to Report Fiscal Second Quarter 2024 Financial Results - GlobeNewsWire
- 4 months ago - embecta-sponsored Educational Symposium and Abstracts at ATTD Highlight Role of Insulin Pumps in the Management of Type 2 Diabetes - GlobeNewsWire